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Abstract
Background: Astrocyte activation is a characteristic response to injury in the central nervous system,
and can be either neurotoxic or neuroprotective, while the regulation of both roles remains elusive.
Methods:  To decipher the regulatory elements controlling astrocyte-mediated neurotoxicity in
glaucoma, we conducted a systems-level functional analysis of gene expression, proteomic and genetic data
associated with reactive optic nerve head astrocytes (ONHAs).
Results: Our reconstruction of the molecular interactions affected by glaucoma revealed multi-domain
biological networks controlling activation of ONHAs at the level of intercellular stimuli, intracellular
signaling and core effectors. The analysis revealed that synergistic action of the transcription factors AP-
1, vitamin D receptor and Nuclear Factor-kappaB in cross-activation of multiple pathways, including
inflammatory cytokines, complement, clusterin, ephrins, and multiple metabolic pathways. We found that
the products of over two thirds of genes linked to glaucoma by genetic analysis can be functionally
interconnected into one epistatic network via experimentally-validated interactions. Finally, we built and
analyzed an integrative disease pathology network from a combined set of genes revealed in genetic
studies, genes differentially expressed in glaucoma and closely connected genes/proteins in the
interactome.
Conclusion: Our results suggest several key biological network modules that are involved in regulating
neurotoxicity of reactive astrocytes in glaucoma, and comprise potential targets for cell-based therapy.
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Background
Astrocyte activation is a hallmark of various CNS injuries
and pathologies, including stroke, trauma, tumor, infec-
tion, and neurodegenerative diseases [1-3]. Upon activa-
tion, astrocytes display altered metabolism and the ability
to preserve CNS homeostasis and support neuronal func-
tion. Reactive astrocytes were shown to reduce damage
during the acute phase of CNS insults [4]. In contrast, pro-
gressive degenerative diseases, such as glaucoma, feature
chronic astrocyte activation that exacerbates damage to
neurons and impairs regeneration of their axons [5,6].
Importantly, a prominent astrocyte reactivation in pri-
mary open angle glaucoma (POAG) is localized to the
optic nerve head, which is also the site of primary damage
to the retinal ganglion cells (RGCs) [7].
In common with many other complex, age-related dis-
eases, neurodegeneration in POAG is associated with a
homeostatic imbalance resulting from environmental fac-
tors and multiple genetic components interconnected
within complex epistatic networks [8]. Such imbalance is
manifested at three interconnected functional levels:
intercellular stimuli, intracellular signal transduction, and
core effectors (i.e. endogenous metabolism, structural
complexes, etc). Disease causes alterations at all three lev-
els. These can be measured by high-content screens that
include differential gene expression, proteomics and
metabolomics, as well as in genetic linkage studies that
connect genes or protein variants to disease onset [9,10].
Recent progress in systems biology has allowed a quanti-
fication, cross-comparison and functional interpretation
of heterogeneous datasets within the framework of
human biological pathways, networks and processes,
which are assembled from a knowledgebase of functional
biological interactions [10,11]. This systems level
approach requires an understanding of connectivity
between the genes and proteins affected in a given disease.
Connectivity is defined by binary protein interactions
with genes, proteins and biologically active compounds
[12]. The biological networks are scale-free but converge
in regulatory nodes and modules, such as major transcrip-
tion factors and receptors [13,14]. Identification of such
key topological elements [15,16] on the networks derived
from disease-related data may reveal potential therapeutic
targets. This approach is particularly powerful for diseases
of complex etiology, such as glaucoma.
Regulation of astrocyte activation, which is associated
with increased neurotoxicity, involves differential activa-
tion of key cellular network modules [17]. To perform in
silico reconstructions of the cellular pathways affected dur-
ing the development of glaucoma, however, data derived
specifically from astrocytes must be used, rather than data
derived from whole-tissue (retina or optic nerve) samples.
It is feasible to suggest that the cell-specific data from
interacting cell types, such as astrocytes and retinal gan-
glion cells, will allow us to analyze differences in trans-cel-
lular crosstalk that are implicated in glaucoma. Here, we
performed functional analysis of the signaling and effec-
tor networks [18] potentially implicated in the patho-
physiology of glaucoma, using both small experimental
and high-content differential data obtained from whole
optic nerves and from reactive ONHAs isolated from the
optic nerves of glaucomatous patients. We reasoned that
the bulk of changes to the ONHA transcriptome would be
disease-related, and subjected the data to meta-analysis at
the level of affected biological processes, and at the level
of biological network topology, using the MetaCore Ana-
lytical Suite [19,20]. This suite of analytical tools, linked
to a comprehensive interaction and biological function
database, is available as a stand-alone application and can
be linked via a "plugin" to other pathway tools such as
Cytoscape [21]. Biological networks were built starting
from either gene expression data alone, or a combination
of high content data sets reflecting multiple levels of infor-
mation flow in the cell. Using a two-step procedure, we
narrowed the set of differentially expressed genes, and
merged it with genes associated in the literature with glau-
coma, thus filling gaps in the fragmented, literature-
derived genetic data. The final direct interaction network
displayed a synergy between these two minimally-over-
lapping datasets, allowing broad characterization of path-
ological changes in reactive astrocytes, and defining
network modules potentially implicated in the shift to
neurotoxicity. Modules regulating such shift represent
therapeutically valuable targets that can be further vali-
dated experimentally.
Results
Functional characterization of gene expression data
Primary astrocytes were purified from the cadaver eye
optic nerve tissue (see Additional File 1, Supplement
Table S1 for clinical information of donor eyes) by two-
step immunopanning procedure and expansion in vitro
prior to analysis, as described [22,23]. A detailed protocol
is provided in Methods. Astrocytes from both normal
(ages 59 ± 13) and glaucomatous (ages 69 ± 13) eyes with
mild, moderate or advanced (1 donor) axon loss were iso-
lated, maintained and processed for analysis in a strictly
similar manner so that cultivation-induced differences on
gene transcription between cell lines would be mini-
mized. Comparison of the two profiles (normal vs. glau-
coma) will, therefore, cancel much of the cultivation-
induced changes, allowing disease-imprinted ones to be
identified. Thus, the gene expression data analysis per-
formed here revealed the changes in the disease-imprinted
ONHAs, an experimental strategy that is often imple-
mented by other investigators working with human dis-
eases [24,25]. Our analysis showed very significant
correlation between transcriptomic changes observed inBMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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human and animal glaucoma; however, we have to admit
that the influence of other factors on gene expression pro-
file of primary cells cannot be fully excluded. Two separate
sets of experimental data, were obtained from a total of
seven normal and eight glaucomatous human donor eyes.
A detailed description of the microarray analysis is given
in Methods section, and in a previous publication [22].
We combined the data from donor Groups #1 and #2,
which contained tissues from four glaucomatous and
three or four normal eyes each (see details in Methods)
into a non-redundant data set comprised of 461 up-regu-
lated genes and 301 down-regulated genes (shown as AFFI
IDs, see Additional File 2), and analyzed it along with
individual data sets from each experimental series sepa-
rately. There was a high abundance of genes with signifi-
cant changes in the expression level between normal and
glaucomatous ONHAs. We limited our analysis to those
genes with the most significant changes in expression
exceeding 2.5-fold differences in RNA abundance. Firstly,
we ranked canonical pathways and gene ontology biolog-
ical processes by the statistical significance of the overlap
between their gene content and genes highly overrepre-
sented in human glaucomatous astrocytes compared to
normal astrocytes. In the enrichment analysis, we used the
over-representation of the DE genes as a parameter to
score the Gene Ontology (GO) functional folders and
Metacore canonical pathway maps. The results were
ranked by increasing the p-value (Figure 1; for the enrich-
ment data on individual datasets see Additional File 1,
Supplement Table S2).
Activated processes and pathways
A major feature of astroglial reactivation following vari-
ous CNS injuries is a profound activation of pro-inflam-
matory and stress response pathways [4,26-28].
Consistently, upregulated genes outnumbered downregu-
lated ones by approximately 50%. Enrichment analysis of
the combined DE data set from this study showed that
highest scoring GO terms for up-regulated genes included
complement activation, signal transduction, regulation of
circulation, inflammatory and innate immune response,
nervous system development and cell adhesion (Figure
1). Metabolic pathways were well-represented among up-
regulated genes, particularly, those encoding three enzy-
matic functions (defines as EC numbers): EC 1.1.1.1 –
alcohol dehydrogenases; EC 1.2.1.3 – aldehyde dehydro-
genases; EC1.14.14.1 – oxidases, cytochromes P450s
(Table 1). Analysis of the data specific for individual
donor groups added cell-cell signaling and lipid metabo-
lism (see Additional File 1, Supplement Table S2). The
most over-represented GO process, complement activa-
tion, scored consistently high in all data sets examined
with nine out of thirty five genes activated (p-value 2.5e-
8). A network built using the "Shortest Path" (SP) algo-
rithm (see Additional File 1, Supplement Table S3 and in
[19]) to connect the genes in this process that changed,
revealed highly-coordinated activation of several comple-
ment factors and regulatory genes, including complement
factor H and clusterin (see Additional File 3, Supplement
Figure S1). Next, we analyzed up-regulated genes associ-
ated with the GO process nervous system development
(33 genes; p-value 4.1e-9). We used these genes as seed
nodes to build process-specific networks using the SP
algorithm: the network featured activation of ephrins,
WNT regulatory proteins, pleiotropin, midkine, and
GRO-I (see Additional File 3, Supplement Figure S2).
Significantly, mapping the combined activation data set
onto canonical pathway maps revealed individual per-
turbed pathways within the larger GO categories. Affected
pro-inflammatory pathways (maps) included, Comple-
ment activation, Signaling via ephrins, TOLL-like (TLR)
receptors and IL-1. Nuclear Factor-kappaB (NF-kB) was
among other top changed stress-response factors (Figure
1). Analysis of the mapped data suggested that increased
activity of ephrin receptors in reactive ONHAs transduced
signals through either PI3K (PIK3CG), intersectin
(ITSN1) or Tiam1 (TIAM1) to RAC1 and CDC42, and
through JNK3/MAPK10 to paxillin, and affected pathways
related to cell migration and neurogenesis (see Additional
File 3, Supplement Figure S3). The established role of
these molecules in regulation of cell movement may
explain the molecular control of de-differentiation and
increased motility of ONHAs, which are characteristics of
reactive astrocytes in general [4,28,29], and of glaucoma-
tous ones in particular [1,3]. Activation of ephrin A4
receptor (EFNA4), which has been shown to inhibit
axonal regeneration via repulsive signaling [30,31], facili-
tated neuronal death in optic nerve and spinal cord injury
models [32]. In contrast, the up-regulation of IL-6,
ephrins B1 and B2 in glaucomatous optic nerves was
interpreted as neuroprotective [33,34]. Similar analysis of
another top scoring map representing VDR-mediated sig-
naling revealed a cross-talk between AP-1 subunit c-Fos
(FOS), androgen receptor (AR), p57 (CDKN1C), oste-
opontin (SPP1) and cytochromes CYP27B1, CYP3A4 in
glaucomatous ONHAs (See Additional File 3, Supplement
Figure S4). Among metabolic maps, biosynthetic path-
ways for bile acid and cholesterol, serotonin-melatonin,
leukotriene 4 and histamine biosynthesis were enriched
(Table 2, also see Additional File 3, Supplement Figure S5)
indicating alterations in lipid membrane biogenesis.
Overall, the enrichment analysis of transcriptional
changes in glaucomatous ONHAs revealed significantly
more activated than down-regulated pathways, which is
consistent with the "re-activation" status of these cells.
Transcriptional activation orchestrated by the transcrip-
tion factors AP-1/c-FOS, VDR, and NF-kB, was modulated
by increased activity of TLR, AR and ephrin receptors. Pro-BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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The enrichment analysis of differential gene expression (microarray) data Figure 1
The enrichment analysis of differential gene expression (microarray) data. The distributions for the top twelve 
canonical maps and GO processes represented by the up-regulated (A, B) and down-regulated (C, D) genes in the combined 
data set. Individual sector areas reflect relative gene representation of each process/map among the top 12 shown. Processes 
and pathway maps were prioritized by p-value; the p-value range for maps and GO processes is color-coded. Bolded processes 
scored in the top 12 in both data sets.BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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inflammatory processes in these cells were mediated by an
increased activity of TOLL-like receptors, NF-kB, MAPKs,
JNK3 and complement system. While increased signaling
via VDR, AP-1, IL-6 and AR in the optic nerve can be
broadly interpreted as a cytoprotective, activation of
ephrin A4 receptor and multiple pro-inflammatory path-
ways represent potentially cytotoxic events, which are
conducive to oxidative stress and possibly harmful to CNS
neurons and their axons. Significantly, enrichment analy-
sis of activated genes across metabolic maps revealed
alterations in cholesterol metabolism that correlated with
increased sensitization of neurons to glutamate in glia-
neuron co-cultures [35]. Similar changes in cholesterol
metabolism were also detected in transcriptomic analysis
of whole optic nerve head tissue in rat experimental glau-
coma [36]. We compared published transcriptomic and
biochemical studies in retina and optic nerves from differ-
ent experimental glaucoma models. Importantly, the pub-
lished data showed multiple similarities with our data
from human ONHAs, particularly in the activation of
innate and adaptive immune responses. Consistent with
our results, animal models of glaucoma showed robust
activation of pathways mediated by AP-1/c-Fos/c-Jun
[5,37,38], NF-B [39], complement [36,40-42], androgen
receptor [39,43] and ephrins [44]. Oxidative stress
response and signaling via NF-B, AP-1 and TLRs have
also been detected in transcriptomic studies of hydrostatic
pressure-induced human ONHAs, and in cytokine-acti-
Table 1: Metabolic pathways activation revealed by gene expression data from glaucomatous ONHAs
Metabolic pathway maps
Enzyme EC # Gene gene ID fold change
(combined set)
common protein name BAB RB CM VDP LB SMB AT
1.1.1.1. ADH1A 124 11.7 Alcohol dehydrogenase 1A ++ +
ADH1B 125 9.7 Alcohol dehydrogenase 1B ++ +
ADh1C 126 5.6 Alcohol dehydrogenase 1C ++ +
1.2.1.3. ALDH1A2 8854 2.2 Aldehyde dehydrogenase(NAD+) ++ +
ALDH1A3 220 5.1 Aldehyde dehydrogenase 1A3 ++
ALDH3A2 224 2.6 Aldehyde dehydrogenase 3A2 ++ +
1.2.1.5 ALDH1A3 220 5.1 retylaldehyde dehydrogenase 1A3 +
1.3.1.20 AKR1C1 1645 20.1 aldo-keto reductase 1C1 +
1.14.14.1 CYP2D6 1565 2.3 cytochrome P450 family 2D6 ++ +
CYP2C9 1559 2.3 cytochrome P450 2C9 ++ + +
CYP1A1 1543 2 cytochrome P450 family IA ++ + +
CYP3A4 1576 1.8 cytochrome P450 family IIIA4 ++ + +
CYP7A1 1581 2.9 cytochrome P450 family 7A1 +
CYP27A1 1593 2.4 cytochrome P450C 27/25 ++
CYP27B1 1594 1.6 calcidiol 1-monooxygenase +
2.1.1.- LCMT2 9836 2.3 leucine carboxyl methyltransferase 2 +
6.3.2.- MID1 4281 3.5 midkine1 +
Abbreviations: BAB Bile acid biosynthesis; RB – Retinol biosynthesis; CM – Catecholamine metabolism; VDP – Vitamin D3 c23 and c24 pathways; LB – 
Leukotrien 4 biosynthesis; SMB – Serotonin-melatonin biosynthesis; AT – Androstenedion testosterone metabolismBMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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Table 2: Distribution of Gene Ontology (GO) processes for the largest Direct Interactions (DI) network of genes up-regulated in the 
combined data set
GO process number of DE genes # genes in a pathway p-value
upregulation, 196 nodes
Cellular physiological process 16 114 2.83e-11
Inflammatory response 23 269 4.26e-11
Regulation of transcription, DNA-dependent 51 1401 7.77e-09
Cell-cell signaling 23 351 7.89e-09
Llipid metabolism 17 197 1.44e-08
Alcohol metabolism 5 7 1.92e-08
Transcription 45 1182 1.97e-08
Positive regulation of cell proliferation 17 215 5.28e-08
Signal transduction 50 1493 1.65e-07
Cytokine and chemokine signaling 5 96 2.07e-07
downregulation, 50 nodes
Cell-cell signaling 17 351 2.76E-13
Regulation of sodium ion transport 4 4 4.39E-10
Norepinephrine-epinephrine regulation of blood pressure 4 4 4.39E-10
Signal transduction 26 1493 7.02E-10
immune response 15 460 2.20E-09
Positive regulation of bone mineralization 4 6 6.54E-09
Transmembrane receptor protein tyrosine kinase activation 4 6 6.54E-09
Heat generation 4 6 6.54E-09
Negative regulation of smooth muscle contraction 4 6 6.54E-09
Norepinephrine-epinephrine vasodilation during regulation of blood pressure 4 6 6.54E-09BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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vated murine astrocytes [45,46]. Gene expression analysis
of EGFR-stimulated rat ONHAs revealed additional com-
monalities in the activation of genes related to cell migra-
tion, ECM reorganization and immune response [47].
Major differences in the transcriptomic data derived from
rodent astrocytes included a lack of activation of VDR-
mediated signaling pathway. This effect may be specific to
glaucomatous human ONHAs. These comparisons lead
us to suggest that the signature profile of the glaucoma-
tous process in reactive astrocytes includes chronic activa-
tion of AP-1, NF-kB, complement, AR, TLRs and cell
adhesion pathways.
Down-regulated pathways and processes
Analysis of down-regulated genes revealed a fewer
number of significantly affected pathways. Perturbed
pathways included PDGF signaling via MAPK cascades,
membrane trafficking and signal transduction via G-I
(Figure 1, also see Additional File 3, Supplement Figure
S6). We identified several levels of inhibitory regulation in
these processes, including structural proteins, signaling
complexes, cellular matrix proteases and intracellular sig-
nal transduction proteins. Down-regulation of many
integrins (a total of twelve in the two donor groups, see
Additional File 1 Supplement Table S4), evidenced pro-
found changes in the adhesion state and cell signaling in
glaucoma. Interactome analysis of the mapped data was
performed to analyze connectivity between down-regu-
lated pathways using the MetaCore network building
tools and gene content from maps (69 genes found on the
12 most significantly down-regulated maps). Analysis of
global connectivity in the networks using the Direct Inter-
actions (DI) algorithm (see Additional File 1 Supplement
Table S3) revealed integrins, TGF-, XIAP, kinase families
A direct interactions (DI) "global" network for the genes up-regulated in glaucomatous ONHAs Figure 2
A direct interactions (DI) "global" network for the genes up-regulated in glaucomatous ONHAs. The network 
was generated using a subset of over-expressed (fold change >2.5) genes from the combined microarray data set as an input. 
The top four interconnected (>20 edges) hubs are marked with cyan circles, less connected (10–20 edges) with pink ovals. 
Green arrows, activation, red arrow, inhibition; short legend is shown below, for a complete legend see Additional File 1 Sup-
plement Table S3.BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
Page 8 of 26
(page number not for citation purposes)
PKC and PI3K as critical hubs interconnecting a compact
network (see Additional File 3, Supplement Figure S7A).
Concerted inhibition of adhesion complexes (see Addi-
tional File 3, Supplement Figure S7B) is a likely explana-
tion for the increased ONHA motility observed in
glaucoma, and may contribute to a change in the physio-
logical role of astroglia upon activation [3,48]. In good
agreement with these findings, studies in an animal
model of glaucoma also showed significant changes in the
expression of ECM components [36], and a toxic decrease
of PKC activity in retinal neurons [49]. However, results of
individual studies on TGF-, and PDGF activation in glau-
coma [50] varied significantly, likely due to differences in
the design, species and cellular populations examined.
Networks for genes differentially regulated in 
glaucomatous ONHAs
We subsequently generated and analyzed merged signal-
ing/metabolic networks from a combined set of 461 up-
regulated and 301 down-regulated genes (see Additional
File 2). A direct interaction (DI) network (see Methods for
algorithm details) was built using the most stringent algo-
rithm that connected only those differentially expressed
genes that are functionally proximal and interact directly
[51]. The largest DI network interconnecting up-regulated
genes contained 196 nodes (Figure 2), while the largest
network of down-regulated genes connected only 50
nodes (see high resolution images in Additional File 3,
Supplement Figures S8 and S9). Both networks were clas-
sified according to their distribution of GO functional
processes (Table 2). The likelihood of finding a DI cluster
of 196 nodes from a random set of 461 genes is very low
(p < 0.0001), reflecting the non-randomness of multiple
activated pathways revealed in ONHAs by network analy-
sis (see Methods for p-value calculation).
Networks for genes with increased expression
Networks can be characterized by a variety of parameters
depicting network topology [52] – distribution of nodes
and hubs (top 25% of nodes by the number of interac-
tions), transcription factors, surface receptors etc. [53].
Typically, hubs on human networks are transcription fac-
tors or membrane receptors, each forming a cluster (mod-
ule) of direct targets and upstream regulators. Twelve
major network hubs constitute the core of the DI network
built from a subset of genes activated in glaucoma. The
top hubs scored by combination of p-value and connec-
tivity included SP1, VDR, NF-B, AP-1/FOS and AR (Table
3), most of which represent redox-sensitive transcription
factors. Major membrane receptors affected in glaucoma
included ICAM1 (up-regulated), PDGF-R  and CCR1
(down-regulated) (Table 4). The gene content for the five
major up-regulated network modules is listed in Table 5.
Transcription factor SP1 forms the largest module with 55
edges, including 48 downstream target genes (Table 3).
This is not unexpected, as SP1 is one of the most prolific
general transcription factors in human cells, and co-acti-
vates a variety of genes in many different conditions [54].
The second largest cluster was formed by the vitamin D
receptor (VDR), 40 edges, 33 targets activated. VDR is a
key nuclear receptor controlling transcriptional activation
of multiple genes in response to inflammation, oxidative
stress and cancer in CNS [55]. Unlike SP-1, activation of
VDR is a less common event, perhaps more specific for
glaucomatous astrocytes. Other CNS pathologies affecting
glia and showing VDR over-expression include astrocyto-
mas, gliomas [56] and reactive astrocytosis in mice [45].
The neuroprotective and immunomodulatory effects of
Table 3: Top hubs differentially activated in the DI network
network hubs hub type edges in out
up-regulated hubs
SP1 TF 58 7 53
VDR TF 40 7 33
NF-kB TF 32 5 27
AP1 TF 21 2 19
AR TF 18 9 8
c-Fos TF 19 10 9
IGF-1 growth factor 17 7 10
c-Myb TF 14 7 7
STAT5B TF 13 9 4
HNF4-alpha TF 12 3 9
E2A TF 12 4 8
IL8 cytokine 11 10 1
MMP2 protease 10 8 2
down-regulated hubs
Interferon-gamma growth factor 19 3 16
STAT1 TF 17 6 11
c-Myb TF 6 0 6
PAI1 ligand 5 3 2BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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VDR activation have been shown to facilitate recovery
after oxidative stress [57], achieved through tight control
of oxidative stress responsive genes and inhibition of
iNOS (NOS2A). In the local differentially-expressed gene
network for glaucomatous ONHAs, VDR activation is trig-
gered by an increase in activity of the upstream regulators
MYB (c-Myb), SP-1 and parathyroid hormone (Figure 3).
AP-1 (21 edges, 19 activated targets) is a major transcrip-
tion factor complex that has been implicated in regulation
of cell proliferation, differentiation, survival and death in
response to physiological stimuli and environmental fac-
tors [58]. Simultaneous up-regulation of the AP-1 subu-
nits c-Jun (JUN), JunD (JUND) and c-Fos (FOS) (the
subunits are merged into an "AP-1" complex to simplify
Figure 2) in glaucomatous ONHAs have translated into
strong activation of a subset of AP-1 regulated targets
shown in Table 5. Co-activation of transcription factors
AP-1 and NF-B in glaucomatous ONHAs is consistent
with their parallel regulation via TLR receptors and
MyD88 [59-62], and a synergistic role in promoting cell
response and survival to various stresses [63]. Impor-
tantly, the gene encoding GATA-3, a transcriptional regu-
lator of TLR2, was elevated in glaucomatous ONHAs. The
activation of AP-1/c-Fos/c-Jun complex has been well
characterized recently in primate model of glaucoma [5].
We compared relative connectivity (experimental vs.
expected) of the top five transcription factors and within
the list of activated genes (2.5 fold) using the MetaCore
Interactome characterization tool ([64] see also descrip-
tion in -Methods). Although NF-kB forms only the third
largest module (32 edges, 27 activated targets) in the net-
work, interactome analysis showed it as the most over-
connected one within activated data set (see Additional
File 1, Supplement Table S5). Combined with a well-
defined role in regulation of inflammation [2,63-66],
responses to stressors (cytokines, complement factors [67]
and reactive oxygen species [64,68,69]), this result may
suggest that NF-kB is the key regulator of neurotoxicity in
reactive ONHAs in human glaucoma. Four NF-B subu-
nits, c-REL, RELA, NFKB2 and NFKBIA, showed activation
at transcriptional level (see Additional File 2). Our data
showed elevated expression of several upstream regulators
of NF-B (AR, EGR3, GATA3 and SATA3/BST2), as well as
downstream targets in glaucomatous ONHAs (Figure 4A).
Transcriptional changes in other well known activators of
NF-B and AP-1, such as TNF, IL-1, and TLRs were
below the cut-off level of our analysis, and examination of
post-translational activation of those was outside the
scope of this study. Alternatively, we performed immuno-
histochemical analysis of optic nerve slices from human
donor tissue (see Additional File 1, Supplement Table S1),
which validated the activation of p50/NFKB1 and p65/c-
REL subunits in glaucoma (Figure 4B). Transcriptional
activation of the androgen receptor (AR) module indi-
cated that glaucomatous ONHAs convert 5-dihydrotes-
tosterone (5-DHT) into 5-androstane-3, 17-diol
(3-diol) more efficiently than normal astrocytes, due to
over-expression of the gene AKR1C6 encoding the
enzyme 3-hydroxysteroid dehydrogenase (3-HSD)
[43]. 3-diol can regulate various cellular functions, and
is connected to the DI network via AR. The DI sub-net-
work for AR does not include 3-HSD (see Additional File
3, Supplement Figure S10), which is markedly up-regu-
lated in glaucomatous ONHA (see Additional File 2) and
has an indirect connection to AR through 3-diol. NF-B
along with its co-regulators, supervillin (SVIL) and
RAD9A, facilitates transcriptional activation of AR in good
agreement with published data [65]. Also consistent with
the literature [66] AR activated downstream targets
Table 4: Top differentially regulated membrane receptors
membrane receptors # edges in out
up-regulated receptors
ICAM1 8 7 1
c-Kit 8 3 5
FGFR2 5 5 0
ITGB3 5 5 0
CD14 2 2 0
ErbB3 2 1 1
IL13RA2 2 2 0
ITGA2 2 2 0
RAIG1 2 2 0
TCRalpha subunit 2 2 0
down-regulated receptors
PDGF-R-alpha 5 5 0
CCR1 4 2 2
Galpha(q)-specific peptide GPCRs 4 4 0
Substance P receptor 3 2 1
Angiotensin II receptor, type-1 2 0 2
Beta-2 adrenergic receptor 2 1 1
Prostacyclin receptor 2 1 1BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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including AQP9, mitochondrial superoxide dismutase
(SOD2), IGF1 and AP-1 (JUND subunit). Given that acti-
vation of AQP9 and SOD2 is characteristic of activated
astrocytes [67], we suggested that 3-diol plays a protec-
tive role in glaucomatous ONHA by increasing the SOD2
expression via AR [68,69].
We analyzed cross-activation within regulatory networks
formed by top five transcription factors. For instance,
MYB and CYP27B1 were co-activated by SP1, AP-1, NF-B
and VDR, IL8 was activated by AP-1, NF-B and VDR. Six
genes were co-activated by both AP-1 and NF-B, four
genes – by NF-B and VDR, and two genes -by NF-B and
AR (Table 5). Network analysis suggested that major tran-
scription factors activated in glaucomatous ONHAs were
involved in complex co-regulation events with each other
and the signaling peptides parathyroid hormone and pro-
lactin (Figure 5). Prolactin, which has been implicated in
neuroinflammatory response [70], showed differential
activation in the microarray data and the prolactin-induc-
ible protein was revealed by proteomics (see Additional
File 1, Supplement Table S6).
Consistent with the results of GO enrichment analysis, we
observed robust activation of a network for innate immu-
nity in glaucomatous ONHAs. Given a non-linear correla-
tion between gene expression and protein translation, and
post-translational activation of complement system, we
Table 5: Regulation of activated genes by transcription factors in the DI network
SP1 VDR AP-1 NF-BA R
Upstream regulation MAPK13 MYB* AR AR CASP1
NFATC1 HR EGR2 BST2 PIN1
PRL IGF1 ELK4 STAT5* NFKB2
PGR PTH MAPK13* REL
SAT PRL PTH RAD9A
STAT5 SP1 SP1 SVIL
WT1 WT1 STAT5* TCF21
VDR* VDR*
Down-stream targets ADH1A GPRC5A ALPL* ALPL* AR SOD2
ADH1B ICAM1 APOD ADH1A* AKR1C1 AP-I/JUND
ADH1C ID1 AR ADH1B* AQP9 AQP9
ALDH1A1 IGF2 CD14* ADH1C* CEBPD * IGF1
ALDH1A2 ITGA2 CRABP2 AKR1C1 CCL17 REL
ALDH1A3 ITGB3 CD40L CYP27B1* CD40L SAT *
ALDH3A2 KIT CYP3A4 ICAM1* CLU
ALPL MMP2 CYP27B1* CLU CDO1
ANGPT2 MPO CYP2C9 CRYZ CDN1A
ASS MYB * IGF1 EGR2 CYP27B1*
ATM OPRM1 IGF2* ELK4 GATA3
BCKDHB PLAT GDF8 GCLC CXCL1*
CEBPD POLE2 GATA3 GPRC5A CXCL3
CD14 PTGES HLA-DQA2 ID2 ICAM1*
CD43 PTHLH ID1 IL13RA2 GCLC
CES1 PURA IL11 IL8 IL13RA2
CHI3L1 SLC4A3 MAF ITGA2* IL8
CXCL1 SLC6A3 IL8 MMP8 HLA-DQA2
CYP27B1 SOD2 MYB MYB * MYB *
CYP3A7 SPP1 MYOD PDYN NCAM1
FBLN1 STAT5 NRP1 PGR* SPP1*
FBLN2 VDR PTGDS PRL* PGES*
FOS PTH* TNFAIP6 SOD2*
HNF4A PTHLH* VCAM1 VCAM1
GYPB RHAG WNT2B
SH3BP5 CXCL2
SLC22A3
SPP1*
VIL1
*Co-regulated by SP1
Co-regulated by NF-B & AP-1 & VDR
Co-regulated by NF-B & AP-1BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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A network for the VDR-regulated genes affected in glaucoma Figure 3
A network for the VDR-regulated genes affected in glaucoma. The gene expression data for the combined data set 
(2.5 fold change) is mapped on the network. The network was generated using the analyze network (AN) algorithm. Network 
objects are vertically stratified according to their cellular localization, which is indicated on the right. VDR edges highlight color 
code: yellow, the upstream regulators; cyan, the downstream targets.BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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tested ONH samples for accumulation of relevant pro-
teins. Our immunohistochemistry and shotgun proteom-
ics data fully supported the transcriptomic data, showing
accumulation of clusterin, complement factors H and B,
and complement protein C3c, a by-product of activation
of the key complement protein C3 in ONH of eyes with
glaucoma (Figures 6A–C). Activation of clusterin and
complement proteins in human ONHAs is in good agree-
ment with recent observations in rat, where it contributed
to retinal ganglion cell (RGC) death induced by chronic
ocular hypertension [42]. Similar activation has been
detected in brain neurons challenged by hypoxic-ischemic
injury [71,72]. On the DI network for glaucoma, clusterin
is connected to two major hubs, AP-1 and NF-B (Figure
2; also see Additional File 3, Supplement Figure S8).
Upstream regulators of clusterin included c-Fos, AP-2A,
beta-endorphin and APP, while C7, C8 and C9 comple-
ment proteins were major downstream targets activated in
glaucomatous ONHAs (see Additional File 3, Supplement
Figure S4). Complement activation has been implicated
in CNS injury and inflammation, brain ischemia, Alzhe-
imer's and Parkinson's diseases, and more recently, in age-
related macular degeneration (AMD) [26,73,74]. Clus-
terin, a major complement regulator, is also a molecular
chaperone [75], and is essential for cell homeostasis.
Excessive accumulation of clusterin in glial cells, however,
correlated with neurotoxicity in brain ischemia [26]; it
promoted microglia activation [76] and to contributed to
RGC loss in a retinal hypoxia-ischemia model [77]. Our
analysis strongly suggests that, similarly to the above-
mentioned pathologies, the inflammatory damage to
optic nerve in POAG is facilitated by excessive production
of complement proteins and clusterin by the reactive
ONHAs.
Networks for genes with decreased expression
Fifty out of a total of 301 genes down-regulated in the
combined data set (2.5 fold threshold) were connected in
MetaCore into a DI network (see Additional File 3, Sup-
plement Figure S9) with a p-value < 0.1. This p-value is
relatively high due to a smaller percentage of functionally
interconnected genes in the subset of genes with
decreased expression. The major hubs in the network are
interferon gamma (IFN-, 19 edges), and transcription
factor STAT1 (17 edges) (Table 3). STAT1 and INF- are
the core hubs in the down-regulation network that are
closely connected to the down-regulated modules c-Myb,
PAI1, PDGF receptor, GPCR G alpha (q)-specific peptide,
Substance P receptor, ATGTR1, TACR1 and CCR1 (Table
4). This network features a number of signaling protein
Activation of the NF-B module in the ONHA-specific disease network Figure 4
Activation of the NF-B module in the ONHA-specific disease network. A. An AN network for upregulated genes 
connected to the NF-B regulated cluster. The network objects regulated by NF-B are grouped according to the GO proc-
esses, and color-coded as shown in the boxes below. The color density of red indicator circles reflects the degree of up-regu-
lation. See Figure 2 and see Additional File 1, Supplement Table S3 for full legend. B. Immunohistochemistry data indicated 
increased accumulation of both p50 (arrows) and nuclear translocation of phospho-p65 (arrowhead) subunits of the NF-kB 
heterodimer in glaucomatous ON tissue. Boxed inserts in left upper corners represent high-maginification images of cells 
showing activated NF-kB subunits. Astrocytes are stained for GFAP (green), nuclei for DAPI (blue), size bars= 50 m.BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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ligands, including thrombopoetin (CCL5), lactoferrin,
substance P, IFN-, neuromedin U, activin beta A, protein
C, CCL8, and is consistent with a decrease in STAT1 and
STAT4, a transcriptional regulators for most of these
genes. STAT1 activation is pro-apoptotic [78], it is
involved in the regulation of vital processes such as cell
cycle, survival [79], and is implicated in ischemic response
and inflammation. Down-regulation of STAT1 is in agree-
ment with the suppression of its key regulators IFN-,
EGFR and PDGF [80], and contributes to activation of
inflammation-associated genes IRF-1, iNOS, and TNF-.
Decreased IFN- and STAT1 signaling, therefore, contrib-
utes to the survival of activated ONHAs in glaucoma.
Integration of proteomics data
The proteomic data were generated in an independent
series of experiments by shotgun MS/MS analysis of
human ONH tissue dissected from eight normal and eight
glaucomatous donor eyes [81]. From a combined set of
250 identified proteins, we selected two condition-spe-
cific subsets of proteins. One was comprised of 32 pro-
teins that were detected only in normal tissue; the second
subset contained 68 proteins that were only detected in
glaucomatous eyes. Only those proteins which were iden-
tified at least twice in one sample group and not identified
in the other, were considered differentially accumulated.
A set of protein IDs was subsequently filtered using a ref-
erence list of proteins with known expression in neurons
(such as 14-3-3 and HSP families), astrocytes, lamina cri-
brosa and blood endothelial cells, which contribute to the
bulk of the optic nerve head tissue. Thirty five out of 49
glaucoma-enriched and 12 out of 32 normal-enriched
proteins matched the objects on MetaCore maps and net-
works (see Additional File 1, Supplement Table S6) and
their corresponding genes were expressed in ONHAs. The
top scored GO processes in the glaucoma-enriched pro-
teomic data included activation of the complement path-
way of the innate immunity, Stress response via heat-
shock protein HSP70 and chromatin condensation (Table
6). Significantly, MS/MS analysis detected complement
factors B and H only in the glaucomatous ONHAs, thus
providing additional validation of the microarray and
immunohistochemistry data (Figure 6) that indicated
robust activation of the complement pathway in glau-
coma.
The combined transcriptomic and proteomic dataset that
included both up-and down-regulated molecular entities
(>2.5 fold change) was used to build a DI network in
order to detect modules and pathways potentially over-
looked by "unidirectional" analysis. The resultant net-
work of 488 nodes (See Additional File 3, Supplement
Figure S11) was interlinked by more then 30 major hubs,
where the top-scoring five included SP1, HNF-4, AR, NF-
B and AP-1/cFos (DE up/down, Table 7). It is notewor-
thy that on this combined network, the VDR hub is scored
lower (less connectivity) than on any of the "unidirec-
tional" networks. In contrast, HNF-4  hub showed a
higher score, suggesting an essential role of this transcrip-
tion factor in cellular regulation of the reactive ONHAs.
Integration of genetic data on the networks
In order to identify a subset of genetically (epistatically)
inter-connected genes encoding physically-interacting
proteins implicated in glaucoma, we built networks using
the manually-annotated list of POAG-linked genes as the
seed nodes. The list of 70 genes, the "G-set", was collected
mostly from epidemiological, genetic and partly from bio-
chemical studies, i.e. the G-set potentially represented epi-
static and/or mechanistic associations between genes,
proteins and the onset of POAG (see Additional File 1,
Supplement Table S7). However, it is noteworthy that
causative relationship with POAG for most of these genes
has not been established and their link with POAG is only
putative. Published gene expression – POAG associations
were not included in the G-list. Epistatic, "causative" asso-
ciations are inherently different from the physical protein
interactions that populate the MetaCore database, which
define a "mechanistic interactome". Since gene expression
– POAG associations were excluded from the G-set, we
did not expect a priori any considerable overlap between
A "core" network showing interactions between the major  hubs of the "global" differential network Figure 5
A "core" network showing interactions between the 
major hubs of the "global" differential network. Tran-
scription factors in glaucomatous ONHAs are involved in 
complex co-regulation events between each other, and the 
signaling peptides parathyroid hormone and prolactin. Hex-
agonal symbols on edges define the type of interaction in the 
link, see Figure 2; Additional Files 1 and 2, Supplement Table 
S3 for complete legend.BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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Complement pathway activation in glaucomatous ONHAs Figure 6
Complement pathway activation in glaucomatous ONHAs. A. The relevant proteomic data (solid red indicator 1) and 
the differential gene expression data (indicators 2 and 3), mapped on the canonical pathway originally characterized in macro-
phage, show cross-verification of the complement pathway activation in glaucomatous ONHAs. Pathway steps confirmed by 
both data types are highlighted with ovals. Differential gene expression data are shown for Group 1 and 2 separately. B, C 
Immunostaining (red) for clusterin (CLU, arrowheads) and complement C3c (C3c) showing increased accumulation of both 
proteins in the lamina cribrosa (LC) region of glaucomatous vs. normal human ONH. Control staining for CLU was performed 
with primary antibodies omitted (B, right panel). DAPI-stained nuclei, blue; size bar = 50 mBMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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the G-set and the list of differentially-expressed genes
(DE-set). Indeed, only nine genes from the G-set were dif-
ferentially expressed in glaucomatous ONHAs. The top-
scoring GO processes for the G-set included response to
wound, cell proliferation, visual perception, blood pres-
sure regulation and inflammatory response while the top
canonical pathways maps were ECM remodeling, the Role
of VDR in regulation and IL1 signaling pathway (Table 8).
Some processes (bolded in Table 8) overlapped with
those that were enriched in the DE-set. The direct interac-
tion network generated from the G-set connected 47 out
of 70 genes into a statistically significant network (p-value
< 0.0001) (See Additional File 3, Supplement Figure S12).
Signaling proteins made up 17 of the 47 nodes on the net-
work, with TNF, AP-1, endothelin-1 (ET-1), IL-1, and
APP being the major hubs. Major transcription factors
included AP-1, P53 and STAT3 (Table 9). As expected, half
of the G-network hubs were receptors and ligands, with
TNF and ET-1 being the top ones, in contrast to the tran-
scriptional factor-regulated DE networks (Table 7).
Despite little overlap between the G-set and DE-set, more
similarities were revealed at the network topology level by
a functional proximity search for differentially expressed
genes within the interactome "neighborhood" of the G-
set. This approach establishes relationships between data-
sets of different types (meta-analysis) using the parameter
of functional proximity, which is defined as one-step
physical interactions between the gene products from dif-
Table 6: Distribution of GO processes in glaucomatous ONHAs revealed by proteomics
Top 10 GO processes (for 35 proteins) p-value maps (for 20 mapped proteins) p-value
Complement activation. Alternative pathway 3.60E-06 CDC42 in cellular processes 1.10E-03
Response to heat 1.10E-05 Alternative complement pathway 1.70E-03
Nucleosome assembly 3.80E-05 Putative ubiquinin pathway 3.10E-03
Complement activation 4.10E-05 Role of ASK1 under oxydative stress 3.20E-03
Glycogen catabolism 5.40E-05 Role of IAP proteins in apoptosis 4.10E-03
DNA DSB repair via homologous recombination 1.00E-04 Glucocorticoid receptor signaling 5.10E-03
Chromosome organization 1.40E-04 Role of Akt in hypoxia 7.80E-03
Carbohydrate metabolism 1.50E-04 Parkin disorder under Parkinson's disease 8.10E-03
Innate immune response 2.20E-04 Role of Parkin in the ubiquitin-proteosomal pathway 8.10E-03
Small GTPase mediated signal transduction 3.10E-04 Urea cycle 3.40E-02
Table 7: Comparison of the hub structure in the DI networks 
built from the three data sets and the combined set
DI networks
DE set DE up/down G-set G/DE combined
SP1* .SP1*T N F  SP1*
VDR* HNF-4*c - J u n * c - J u n *
NF-kB* AR* ET-1 P53*
AP-1* NF-kB* STAT3* VDR*
AR* AP-1*I L - 1  STAT1*
c-Fos* STAT1* AP-1* AP-1*
STAT5* c-Fos* c-Fos*T N F 
HNF-4*c - R e l * E G F R I L - 1 
c-Myb* VDR*P 5 3 * E G F R
IGF-1* c-Myb* iNOS IFN
*transcriptional factors
bolded, top scored hubs shared by most networksBMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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Table 8: Distribution of GO processes and pathways maps for the "literature" G-set gene list
Top GO processes p-value Pathway maps p-value
Response to wounding 7.09E-07 ECM remodeling 2.00E-12
Cell proliferation 3.63E-06 VDR in regulation of differentiation 1.10E-06
Visual perception 2.08E-05 Heme metabolism 3.90E-06
Blood pressure regulation 2.34E-05 IL1 signaling pathway 5.70E-06
Heart development 2.92E-05 MIF in innate immune response 2.30E-05
Inflammatory response 7.58E-05 Integrin outside-out signaling 1.10E-04
Peptide transport 8.03E-05 MAPK cascade. Nuclear function of p38-MAPK 1.20E-04
Cytosol to ER transport 8.03E-05 HGF signaling pathway 1.50E-04
Positive regulation of I-kB/NF-kB cascade 9.90E-05 JNK pathway 1.80E-04
Skeletal development 1.11E-04 Plasmin signaling 2.30E-04
Bolded, processes and maps similar to those revealed with the gene expression data
Table 9: The basic network statistics ("top tens") for the combined G/DE/DI network
Hubs TFs Signaling peptides GO processes
SP1 ANDR Amphiregulin Regulation of transcription from RNA Pol II promoter
c-Jun AP-1 APOE Skeletal development
P53 Bcl-6 BDNF BMP signaling pathway
VDR c-Fos BMP2 Transcription
STAT1 c-Jun BMP4 Cartilage development
AP-1 c-Myb BMP5 Cell differentiation
TNF c-Rel BMP7 Regulation of transcription, DNA-dependent
IL-1 C/EBPbeta COL1A1 Positive regulation of progression through mitotic cell cycle
EGFR E2A COL4A4 Development
IFN ESR1 Collagen III Mammalian eye developmentBMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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ferent sets [82]. We built a set of networks using the G-set
gene content as input nodes and the Analyze Networks
(AN) algorithm. We then mapped the expression data
onto the AN networks. The AN algorithm prioritizes sub-
networks based on relative enrichment with experimental
(gene expression) data and canonical pathways (See Mate-
rials & Methods). This helped us to identify the proximal
DE-set network objects and to fill the gaps in the frag-
mented disease association data (see Additional File 3,
Supplement Figure S13). After analyzing the 50 top scored
AN networks built from the G-set, we identified 37 up-reg-
ulated and 20 down-regulated genes (see Additional File
1, Supplement Table S8). The majority (32 out of 57) of
genes identified in the interactome neighborhood of the
genetic network were also present on the global DI net-
work for activated genes and proteins (see Additional File
3, Supplement Figures S14 a, b).
We then merged the G-set with the 57 DE-set genes from
close interactome neighborhood to identify possible con-
nectivity between the networks originating from genetic
and gene expression data. The combined data set of 119
genes included only nine genes common to both data
sets. Differential activation of another four genes from the
G-set was suggested by the proteomic data. GO distribu-
tion showed enrichment in the processes: regulation of
transcription, BMP signaling pathway, cell differentiation
and development, in the combined G- and DE-sets (Table
7). The stringent DI algorithm connected 102 out of 119
nodes into one combined G/DE network (see Additional
File 3, Supplement Figures S14 a, b), with a p-value <
0.0001 (see Additional File 1, Supplement Table S9). It
narrowed the interaction gaps between the literature-
derived G-set data. An important feature preserved in both
DE and G/DE networks is the synergy between the major
transcription factors AP-1, SP1, VDR, AR and NF-B. As
the G-set data are not cell type- or tissue-specific, the con-
servative hub structure of the disease network may repre-
sent a core feature of the glaucomatous process across all
eye tissues. Some major hubs present only in the G/DE
network included P53, STAT1, TNF, IL-1, EGFR, and
IFN-  (Table 7), from which STAT1 and P53 hubs
increased their relative scoring, suggesting that their
potential role in astrocyte activation in glaucoma should
be further investigated.
Discussion
The ultimate goal of our functional analysis of glaucoma-
related high content data was reconstruction of the condi-
tion-specific model at three levels: i) stimuli, i.e. the
endogenous and exogenous (environmental) signals,
which trigger the disease condition; ii) intracellular sign-
aling activated in the disease; and iii) effectors – the cellu-
lar processes, structural complexes and metabolic
pathways altered by aberrant signaling in the disease.
Changes at the effector level should be consistent with the
observed disease manifestations in molecular profile and
phenotype. While complex exogenous signals are known
to include genetics, age, mechanical damage, etc., our net-
work analysis has revealed molecular modules that are
activated intracellularly, and suggests plausible disease
effectors in glaucomatous ONHAs. This analysis suggests
that intracellular signaling in reactive ONHAs in response
to glaucomatous conditions is mediated by a synergy of
key transcription factors VDR, NF-B, AP-1 and AR. These
changes are paralleled by decreased signaling via
integrins, PDGF and STAT1, which might be insulting to
the retinal ganglion cells, since these molecules control
adherence, while the motility of glaucomatous astrocytes
is likely to be disruptive to their metabolic support func-
tions [2,3,48]. Integration of the gene expression and pro-
teomic data for ONHAs confirmed substantial activation
of the innate immune response and suggests that this is
one of the key effector events in activated astrocytes,
which has been also detected in recent gene expression
studies [42,83]. At the level of metabolism, our analysis
revealed coordinated activation of endogenous alcohol
and aldehyde dehydrogenases, which is consistent with
increased metabolic activity and oxidative stress response
[69,84]. Similar activation of these pathways has been
shown in the brain of Alzheimer's sufferers, and is likely
to play a protective role in detoxification of reactive inter-
mediates of lipid peroxidation [85]. Significant activation
of phospholipase A2 and it's receptor PLA2R1, which are
involved in a complex network linking receptor agonists,
oxidative agents, and proinflammatory cytokines to the
release of arachidonic acid [86], represents a pro-inflam-
matory effect of glial activation also observed in brain
pathologies [87].
Our network analysis demonstrated activation of poten-
tially neurotoxic and neuroprotective programs in
ONHAs in response to glaucomatous ON injury. We
found that NF-B is significantly over-connected on the
DI and AN networks, showing links to both programs. In
contrast to the well known pro-survival role of this tran-
scription factor, recent studies have demonstrated a pro-
found negative impact of NF-B activation on neuronal
survival in various CNS pathologies [88-91]. Our analysis
suggests that the activation of a NF-B-controlled tran-
scriptional program in glaucomatous ONHAs facilitates
pro-inflammatory events and is, therefore, potentially
neurotoxic. It has been demonstrated that in the glia reac-
tivated with LPS, amyloid-beta, elevated hydrostatic pres-
sure, cytokines or double-stranded RNA, NF-B induction
correlated with neurotoxic levels of NOS-2, MMPs, JNKs
(MAPK8-10), complement, clusterin and cytokines
[6,45,92-94]. Activation of several NF-B subunits dem-
onstrated at the levels of gene transcripts, proteins and
over-connectivity with upstream regulators and down-BMC Medical Genomics 2009, 2:24 http://www.biomedcentral.com/1755-8794/2/24
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stream targets on the disease network, supports the notion
that NF-B is key convergence hub in this pathology. In
contrast to systemic inhibition of this vital transcription
factor that would have a negative impact on neuronal sur-
vival, as shown in recent studies utilizing sulfasalazine
inhibitor [95] or a knockout mouse model [96], our
experimental data strongly endorse astroglial NF-B as a
potential target for a cell-level inhibition in glaucoma
therapy.
Conclusion
Direct networking of gene products via protein interac-
tions can be used to identifying modules of epistatic inter-
action between disease related genes, as described for
yeast metabolism [97]. As we showed previously [10],
major topological features of differential networks repre-
sent molecules affected by the disease process, and repre-
sent potential targets for therapeutic intervention. In this
work, we took advantage of the functional analysis capa-
bilities and database of molecular interactions in Meta-
Core and cross-referenced two experimental datasets,
proteomic and genetic, which are otherwise poorly com-
parable. Using a two-step procedure, we narrowed the set
of differentially expressed genes to fifty seven genes (DE-
set) most relevant to the G-set of genes associated in the
literature with glaucoma, effectively filling the gaps in the
fragmented literature-derived genetic data. Our analysis of
glaucomatous astrocytes indicated that the synergistic
activation of the major hubs SP-1, VDR, NF-B and AP-1
in response to oxidative stress and mild ischemia associ-
ated with glaucoma, orchestrates genome-wide changes in
the transcriptional profile and chronic activation of
ONHAs. In contrast to the pro-survival effects of VDR, AP-
1and AR, the harmful effects of chronic activation of
major downstream effectors such as NF-B, clusterin,
complement and ephrin A4 receptor are likely to be
responsible for tipping the balance in the optic nerve
microenvironment towards neurotoxicity and inhibition
of regeneration. Combined, these glial factors could
actively contribute to the retinal ganglion cell death in
glaucoma by exacerbating inflammatory damage to chal-
lenged axons. Our results imply that the suppression of
the major downstream effectors may represent feasible
strategy for glia-targeted therapy of glaucoma, ensuing fur-
ther experimental validation of these targets.
Methods
Optic nerve Astrocytes
Cultures of human ONHA were generated as previously
described [23]. Briefly, ONH were dissected and processed
within 24 h of death. Four explants from each lamina cri-
brosa were dissected and placed into 25-cm2 Primaria tis-
sue culture flasks (Falcon, Lincoln Park, NJ). Explants
were maintained in DMEM-F12 supplemented with 10%
FBS (Biowhittaker, Walkerswille, MD) and PSFM (10,000
U/ml penicillin, 10,000 g/ml streptomycin and 25 g/
ml amphotericin B; Gibco/BRL, Gaithersburg, MD). Cells
were kept in a 37°C, 5% CO2 incubator. After 2–4 weeks,
primary cultures were purified by using modified two-step
immunopanning procedure described by Mi and Barres
[98]. Purified cells were expanded after characterization
by immunostaining for astrocyte markers GFAP and
NCAM as described [98,99]. Second passage cell cultures
were stored in RPMI 1640 with 10% DMSO in liquid
nitrogen until use. For each set of experiments, cells were
thawed and cultured for one more passage so that suffi-
cient cells from the same batch were available in each set
of experiments. Astrocytes from both normal and glauco-
matous eyes were cultivated similarly in parallel experi-
ments. This ensured that differential transcriptomic data
obtained from them have been normalized for cultiva-
tion-induced changes, and showed only disease-
imprinted profile changes as reported by others [24,25].
Seventeen pairs of normal human eyes from donors (age
58 ± 12) with no history of chronic CNS or eye disease
were obtained from the National Disease Research Inter-
change (NDRI) and from Mid-America Eye Bank (St.
Louis, MO) within 2–4 h of death (see Additional File 1,
Supplement Table S1). A total of eight eyes from six
donors with documented primary open angle glaucoma
(POAG) (age 73 ± 9) were obtained for the analysis. Seven
normal eyes were used to generate astrocytes for microar-
ray analysis, the rest were used for real time RT-PCR. ONH
were dissected and processed within 24 h of death to gen-
erate astrocyte cultures. To test whether the normal eyes in
this study may have had hidden optic nerve disease, and
to assess damage in samples from POAG. Samples of the
myelinated nerves were fixed in 4% paraformaldehyde,
post-fixed in osmium, embedded in epoxy resin, and
stained with paraphenylendiamine to detect axon degen-
eration [100,101].
Human ONHA microarray data
The microarray data for two separate donor groups,
Group 1 and Group 2 (four or three normal and four eyes
with glaucoma in each group, a total of fifteen human
optic nerve samples) were obtained from primary human
ONHAs, type 1B, derived from glaucomatous and from
normal control eyes as described previously [22]. The
microarray analysis of Groups #1 and #2, which was sep-
arated by a two year time interval possessed significant
difference in the mean threshold levels of signal intensi-
ties and, therefore, corresponding data were analyzed sep-
arately. In total, we analyzed three differential expression
(DE) data files: donor Group 1, revealed 322 up-regulated
and 152 down-regulated Affymetrix gene IDs (that corre-
spond to 298 and 130 non-redundant genes by HUGO
nomenclature, respectively); donor Group 2, (357/335
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combined dataset comprised of 461 up-regulated and 301
down-regulated AFFI IDs/genes (see Additional File 2).
The latter set was obtained by pair-wise comparison of all
disease vs. all normal samples. All original data were
deposited in GEO (accession #GSE2378). A portion of
these data (referred to as donor Group 1) has been pub-
lished previously [22]. The raw normalized data were sta-
tistically analyzed as described below and used to obtain
the gene-specific ratios of differential expression. In total,
we analyzed three data files composed of genes with fold
change exceeding 2.5: donor Group 1, revealed 322 up-
regulated and 152 down-regulated Affymetrix gene IDs
(that correspond to 298 and 130 non-redundant genes by
HUGO nomenclature, respectively); donor Group 2,
(357/335 up- and 271/261 down-regulated AFFI/HUGO
IDs). In addition, 484 up-regulated and 323 down-regu-
lated genes comprised the combined non-redundant set
of genes with known functions, in which 461 and 301,
respectively, were recognized as "network objects" in the
MetaCore database (see Additional File 2).
Human ONHA proteomic data
Proteomic data was generated by shotgun MS/MS analysis
of human ONH tissue from eight normal and eight glau-
comatous donor eyes as described previously[81]. From
the combined set of 248 proteins identified by this analy-
sis we selected two subsets: proteins detected only in nor-
mal tissue (31 IDs) and those found only in
glaucomatous eyes (67 IDs). Shotgun MS-identification
of proteins has very limited ability in ruling out the
absence of a protein, so for further analysis we only
selected those proteins that were identified only in glauco-
matous tissue. To focus on the data relevant to astrocytes,
the selected protein IDs were filtered against proteins with
known association with neuronal axons, which formed
the bulk of the optic nerve head tissue. Of the remaining
50 IDs, 35 had links to MetaCore maps and networks and
were used in our analysis. The expression of all 35 pro-
teins in astrocytes was confirmed by microarray data.
Statistical analysis of gene expression data
Affymetrix microarray data contain intensity values and
absent/present flags for each probe set. There were a total
of sixteen sets of data used in this study, eight with glau-
coma and eight with normal expression. The calculations
and data analyses were done with R statistical software
http://www.r-project.org. First, we tested whether or not
the gene expression values from the glaucoma set were dif-
ferent overall from those of the normal set. This was done
by comparing two statistical models:
yi = ei, i = 1,..., number of genes,  grand mean, ei – error,
and
yij = i + eij, i = 1,2, j = 1,..., number of genes, i – group
mean, ei – error.
The first model ignores the presence of two different
groups. In the second model, we differentiate between the
means of the glaucoma and normal groups.
Next, we analyzed the expression of every gene in the glau-
coma set with respect to the normal set. Since we had data
from eight independent experiments, we could not obtain
accurate results from pairing each set of glaucoma data
with a unique set of normal data. Every possible glau-
coma-normal combination was therefore considered for
every gene. The number of such combinations is n*m,
where n is the number of glaucoma values, and m is the
number of normal values. When no expression values are
missing for a specific gene in any of the experiments, there
are 16 combinations for every of the two donor groups.
The ratios of glaucoma to normal expression were then
calculated. To allow the construction of a linear model
from the data, base-ten logarithms were taken for each
ratio.
The table of results consists of eight columns (see Addi-
tional File 1, Supplement Table S10). The first column is
the gene; the second is the mean of the log ratios. To help
visualize the results, the third column contains the ratio
itself, such that the values for all over-expressed genes are
glaucoma/normal ratios, and the values for under-
expressed genes are negative normal/glaucoma ratios. The
fourth column shows the standard error (se) for the mean
log ratio of a gene, which is defined by  , where 
is the sample variance, and n is the size of the sample.
The next two columns present the bounds of the 95% con-
fidence interval for every mean log ratio. Confidence
intervals were calculated with Bonferroni adjustments,
since we wanted to maintain an overall confidence of 95%
while considering all genes at once. Each confidence inter-
val is defined by
Due to the very large number of degrees of freedom
(189375), values from the standard normal distribution
could also have been used instead of those from the Stu-
dent t distribution. The seventh column has the "TRUE"
value if the 95% confidence interval for that log ratio con-
tains 0 and "FALSE" if it does not. That way it is easy to see
which genes have glaucomatous expression levels differ-
ent from the normal tissue expression level of the same
genes.
 μ
ˆ  2
n ˆ 
2
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Another way to interpret the results is to use p-values, i.e.
the smallest levels of significance for which one can con-
sider the corresponding log ratio means is to be different
from zero. If a given p-value is smaller than the chosen
level of significance for the test, then it can be concluded
that the gene is expressed. A p-value is calculated by P(Z <
(- gene/se)) + P(Z > ( gene/se)), Z ~ N(0, 1). A Bonferroni
adjustment is then applied to this result to ensure small
enough overall error. Tables were created from the results
with genes that have expression ratios greater than a cho-
sen ratio or smaller than the negative chosen ratio and p-
values smaller than 0.05. Another pair of columns con-
tains the average glaucoma and normal expression levels
for every gene, the standard error for these values and the
95% confidence intervals to identify the ranges for the
true averages. A present flag was given to every gene that is
marked as present in at least three out of four experiments.
Otherwise the flag is set to "Absent".
Functional analysis of the data
The functional analysis workflow consists of series of
qualitative and quantitative procedures for parsing large
datasets into smaller, functionally-meaningful subsets,
such as linear signaling and metabolic pathways, and cel-
lular and molecular processes. The overlap between
genes/proteins within a functional category and the com-
ponents of a high-content dataset identified as meaning-
fully altered can be given a p-value based on the
likelihood of this overlap happening by random chance
(see below). Multiple functional categories can be scored
for each dataset, a procedure referred to as enrichment
analysis[102]. The distribution of categories reflects their
relative relevance to the condition within the dataset. We
used the content of gene ontologies from OnthoExpress
[35] in MetaCore™ (GeneGo Inc, MI, http://
www.genego.com) for enrichment analysis of genes dif-
ferentially expressed in reactive vs. normal ONHAs.
Interactome analysis for relative connectivity
The goal of the analysis was to identify hub proteins, par-
ticularly transcription factors, with a significantly large
number of interactions within the set of interest. This type
of meta-analysis a part of Interactome tool of the Meta-
Core and allows calculation of relative connectivity for a
hub as a measure of interactions enrichment in experi-
mental data vs. expected for a random data set of a similar
size. This characteristics serves as better indication of rele-
vance of a hub gene/protein for the condition-induced
changes within a dataset as compared to the absolute
number of interactions, where highly prolific hubs (SP-1,
P53, etc.) dominate routinely. Relative connectivity of
major transcription factors was measured as described by
Wood and co-authors [64]. We calculated the interactions
of proteins within a set of interest and compared that with
the number of connection both in the global protein
"interactome"and in the experimental subset. We
assigned statistical significance by using the cumulative
hypergeometric distribution as follows:
 where
N – the number of proteins (protein-based network
objects) in our global "interactome" extracted from Meta-
core
n – number of proteins derived from the sets of genes of
interest
D – the degree of a given protein in the global "interac-
tome" database
k – the degree of a given protein within the set of interest
The p-value calculated above gives the probability of
observing k or more interactions of a given protein (with
degree D in global network) by random chance within the
set of interest (of size (n)).
The probability of observing "under-connected" con-
nected proteins can be calculated by 1-p(k).
The input lists of genes were converted to protein-based
network objects which have been used in our analysis. The
resulting network objects sets were divided by subsets
based on the molecular function (receptors, ligands, etc.).
Identification of differentially expressed genes in close 
proximity to the genetic network
Data of different origin can be connected on the same net-
works. For instance, genes implicated in the onset of the
disease can be linked with differentially expressed genes
via physical interactions between their corresponding pro-
tein products. The network analysis process does not
require clustering or statistical analysis other than when
defining the probability (p-value) of the assembly of a
network of a certain size out of randomly selected relevant
nodes (described in the Methods). Each network is, there-
fore, unique for the data set at the level of specific pro-
teins, subunits and binary interactions. The Analyze
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Networks (AN) algorithm (see Additional File 1, Supple-
ment Table S3) connects every node with all others by
unidirectional shortest paths using the G-set as the input
nodes. This algorithm builds sets of the overlapping small
networks consecutively covering all root nodes from the
input list. The essential difference between DI and AN net-
works is that the latter allow non-root objects to form con-
nectors between root nodes. In each of the top-scoring 50
networks, 40 – 55% of the objects were root nodes from
the G-set. Next, we mapped the differential expression
data (DE-set) onto AN networks using the filter experi-
ments tool in MetaCore, which mainly maps the non-root
nodes. Between one and seven differentially expressed
"close neighbor" genes were typically located on each of
AN networks (see example in See Additional File 3, Sup-
plement Figure S13). In our data, the majority (32 out of
57) of the interactome neighborhood genes were also
present on the global DI network (See Additional File 3,
Supplement Figure S14). Since the global DI network
included only 277 out of 807 input genes (34%), one
would expect only 19 out of 57 genes from the vicinity list
to overlap with the DI network list with random distribu-
tion. The 56% overlap between two gene expression lists
(p-value of such an event is 0.005) indicates a strong cor-
relation between the genetic network and the gene expres-
sion network for glaucoma.
Quantitative RT-PCR
To validate the microarray data, total RNA was extracted
from ONHAs that were obtained from normal and glau-
comatous eyes using Qiagen RNAeasy mini kits (Qiagen,
Valencia, CA). RNA was then purified and quantified by
measuring absorbance at 260 nm and treated with RNase
free DNase (Ambion). Single strand cDNA was prepared
from 2 g total RNA using SuperScript II reverse tran-
scriptase (Invitrogen). 5 l of 1:20 -1:80 diluted cDNA
were used for reaction with 2× Bio-Rad SYBRGreen Super-
Mix (Bio-Rad Laboratories Inc, Hercules, CA) in 25 l, and
quantitative PCR was performed by monitoring in real
time the increase of fluorescence of SYBR Green using the
MyiQ (Bio-Rad Laboratories Inc). Custom primers were
designed using the Primer Express program (PE Applied
Biosystems) for 22 transcripts representing major network
hubs as well as randomly picked DE genes. At least one
primer crossed the exon-exon boundary to prevent
genomic DNA amplification. Primer quality (lack of
primer-dimer amplification) was confirmed by melting
curve analysis. Sequences of primers are available upon
request. Relative quantification of gene expression was
performed using the standard curve method (User Bulle-
tin 2 of the ABI Prism 7700 Sequence Detection System,
PE Applied Biosystems, Forster City, CA). Serial dilutions
(1:4: 1:16, 1:64, 1:256) of mixtures of all samples were
used for standard curves. For each cell culture the relative
amount of mRNA for a target gene was normalized to the
relative amount of reference gene RNA (18S RNA). Then,
the average of normalized relative expression levels for all
glaucoma and average for all normal samples for each
gene was calculated. The higher average (glaucoma or nor-
mal) was divided by the lower average (normal or glau-
coma) to determine fold change for each gene. The fold
increase in glaucoma (glaucoma higher than normal) was
expressed by positive numbers and fold decrease (normal
higher than glaucoma) by negative numbers (see Addi-
tional File 1, Supplement Table S11). Quantitative PCR
data for validation of the expression of the three 3HSD
isoforms used isoform-specific probes and primers previ-
ously described [43]. The 3HSD probes have full homol-
ogy to the AKR1C3 gene sequence and recognized mostly
AKR1C3. The sequence of the AKR1C1  probe has full
homology to the AKR1C1 and AKR1C2 gene isoforms and
recognizes both of them.
Network visualization and analysis
The set of genes differentially expressed at the cut-off value
of 2.5-fold was uploaded into the MetaCore Analytical
suite (GeneGo, Inc. St. Joseph, MI). MetaCore is a web-
based computational platform primarily designed for the
analysis of high-content experimental data in the context
of human metabolic and regulatory networks and path-
ways. MetaCore includes a manually-curated database of
human protein interactions, metabolism and bioactive
compounds. Analysis was conducted in accordance with
the application manual and has been described previously
[102,103].
Scoring and prioritization of networks according to the 
relevance of input data
In most cases, high-content experimental datasets are very
large and may include data on thousands of genes. In such
cases, the issue of prioritizing networks and network mod-
ules is important. Prioritization can be based on different
parameters, but generally follows the procedure described
below. The data set is divided into two random overlap-
ping subsets, in which the size of the intersection between
them represents a random variable with a hypergeometric
distribution. We applied this for numerical scoring and
prioritization of the node-centered networks. Let us con-
sider a general data set size of N with R marked objects/
events (for example, the nodes with expression data). The
probability of a random sub-set size of n to include r
marked events/objects is described by the distribution
The mean of this distribution is equal to:
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Where q = R/N defines the ratio of marked objects.
The dispersion of this distribution is described as:
It is essential that these equations are invariant in terms of
exchange of n for R which means that the "subset" and
"marked" are equivalent and symmetrical sets. Impor-
tantly, in the cases of r > n, r > R or r <R + n - N, P(r, n, R,
N) = 0
We used the following z-score equation for comparison
and prioritization of node-specific SP sub-networks
Where N is the total number of nodes after filtration, R is
the number of nodes in the input list or the nodes associ-
ated with experimental data, n is the number of nodes in
the network,r is the number of the network's nodes asso-
ciated with experimental data or included in the input list,
and  and  are the mean and dispersion of the hyperge-
ometric distribution described above.
P-value and evaluation of statistical significance of 
networks
The p-values throughout MetaCore – for maps, networks
and processes – are all calculated by using the same basic
formula: a hypergeometric distribution in which the p-
value essentially represents the probability of a particular
mapping arising by chance, given the numbers of genes in
the set of all genes on a particular map/network/process
and genes in an experiment (see the formula below). For
a network of a certain size we can evaluate its statistical
significance based on the probability of its assembly from
a random set of nodes the same size as the input list (see
Additional File 1, Supplement Table S12). We can also
evaluate the network's relevance to biological processes or
any other subset of nodes. Let us consider a complete set
of nodes in the network that are divided into two overlap-
ping subsets. These subsets represent the nodes that are
linked to a certain pre-defined node list. In the general
case, these subsets are different but overlapping, and we
assume that the intersection is large enough and non-ran-
dom. We do not consider a situation where the intersec-
tion is small but non-random. The null hypothesis states
that the subsets are independent and, therefore, the size of
the intersection satisfies a hypergeometric distribution.
The alternative hypothesis states that there is positive cor-
relation between the subsets. Based on these assumptions,
we can calculate a p-value as the probability of intersec-
tion of two random subsets from the same set.
Where: N-total number of nodes in MetaCore Database, R
– number of network's objects corresponding to the genes
and proteins in the list; n- total number of nodes in each
map or network generated from the list; r- number of
nodes with data in each map or small network generated
from the list.
Statistical test for network non-randomness
If we consider a list of nodes corresponding to experimen-
tally altered genes and proteins, this pre-selected list is
then used for building the networks using one of the algo-
rithms. The statistical significance of the resulting net-
works can be defined using the DI algorithm, which
displays only the nodes from the input list connected to
each other in one step. We can now evaluate the probabil-
ity of random generation of an interaction cluster of equal
or larger size than the number of nodes in the DI network.
After defining the list of nodes, a random subset is
selected from this list, the network is built with the same
algorithm and settings, and the size of the largest network
cluster is calculated. The procedure is repeated many
times (e.g. 1000 or 10,000 trials) and statistics are accu-
mulated on the number of times the largest cluster of a
certain size is generated. The ratio of the number of ran-
dom clusters the same as the original DI network or larger
compared to the total number of trials is a parameter
describing the significance of the input list. For example,
we calculated these parameters in 10,000 trials using the
gene list with unique identifiers from Affymetrix U95
human array as the initial set.
Among the total gene set recognized by MetaCore on the
Affymetrix U95A array were 5117 network nodes; random
samples of 50 to 500 nodes were selected as an input for
network building using the DI algorithm with the same
settings as for the original network. The mean cluster size
and p-values are presented in see Additional File 1, Sup-
plement Table S12. The calculated p-value of the large DI
cluster of 196 out of 484 random nodes was < 0.0001.
Calculation was based on statistical probability that 196
genes form a network by random chance.
Immunohistochemistry
Sagittal sections of four human normal, and four glauco-
matous optic nerve heads, 6 m thick, were used for
immunodetection of glial fibrillary acid protein (GFAP),
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clusterin and complement protein C3c. Human anti-clus-
terin antibodies were purchased from Upstate (Lake
Placid, NY) and applied at a dilution of 1:200; human
anti-C3c sheep polyclonal antibodies (Abcam, Cam-
bridge, UK) were used at a dilution of 1:250. For double
immunofluorescence staining of reactive astrocytes we
used rabbit polyclonal antibody against human GFAP
(Sigma, St. Louis, MO) diluted 1:150. The distribution of
the primary antibodies was visualized using anti-mouse
IgG or anti-sheep IgG secondary antibody conjugated to
the Alexa 568 fluorochrome (Molecular Probes, Eugene,
OR). To visualize cell nuclei, DAPI stain (Molecular
Probes) was applied at the dilution 1:10,000 in PBS buffer
(Sigma). For negative controls, the primary antibody was
replaced with the appropriate non-immune serum. To
control for cross-reactivity in double immunofluores-
cence, sections were incubated with secondary antibody
only. Sections of normal and glaucomatous eyes were
stained simultaneously to control for individual varia-
tions in immunostaining. Stained slices were then ana-
lyzed by confocal microscopy using a Zeiss LSM 510
microscope equipped with argon, HeNe and UV lasers for
multiple fluorophore excitation.
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